The liver and muscle share many metabolic and physiological pathways; thus, MASLD and muscle impairment share the consequences of hepatokines, myokines, insulin resistance, oxidative stress, and chronic inflammation. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.